Presentation Title

Characterization of Dormancy in Doxycycline-resistant MCF-7 Human Breast Carcinoma Cells

Start Date

November 2016

End Date

November 2016

Location

Surge 173

Type of Presentation

Oral Talk

Abstract

Breast cancer is among the most prevalent forms of cancer affecting women in the United States. Chemotherapy, while efficacious, also promotes the development of drug resistant cells. One mechanism that is thought to contribute to resistance is cancer cell dormancy – a rare and reversible cancer cell phenotype that prevents chemotherapy drugs from targeting tumor cells and makes cancer difficult to detect. This study examines the molecular mechanisms behind resistance and dormancy in MCF-7 breast carcinoma cells. The data suggests that (1) doxycycline-resistant MCF-7 cells exhibit morphological changes, (2) doxycycline treatment leads to decreased cell cycle progression as compared to untreated MCF-7 parental cells. Further exploration of this phenomenon will be performed via western blot analysis of protein expression and flow cytometry analysis of the cell cycle in the coming months. These investigations will provide insight into the mechanisms of tumor dormancy which may drive discovery of novel therapeutic interventions.

This document is currently not available here.

Share

COinS
 
Nov 12th, 3:00 PM Nov 12th, 3:15 PM

Characterization of Dormancy in Doxycycline-resistant MCF-7 Human Breast Carcinoma Cells

Surge 173

Breast cancer is among the most prevalent forms of cancer affecting women in the United States. Chemotherapy, while efficacious, also promotes the development of drug resistant cells. One mechanism that is thought to contribute to resistance is cancer cell dormancy – a rare and reversible cancer cell phenotype that prevents chemotherapy drugs from targeting tumor cells and makes cancer difficult to detect. This study examines the molecular mechanisms behind resistance and dormancy in MCF-7 breast carcinoma cells. The data suggests that (1) doxycycline-resistant MCF-7 cells exhibit morphological changes, (2) doxycycline treatment leads to decreased cell cycle progression as compared to untreated MCF-7 parental cells. Further exploration of this phenomenon will be performed via western blot analysis of protein expression and flow cytometry analysis of the cell cycle in the coming months. These investigations will provide insight into the mechanisms of tumor dormancy which may drive discovery of novel therapeutic interventions.